Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company's quarterly revenue was up 30.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.38) EPS. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX traded down $0.36 during midday trading on Thursday, hitting $6.32. 4,341,169 shares of the stock were exchanged, compared to its average volume of 5,679,481. The company has a 50 day moving average price of $6.68 and a 200-day moving average price of $7.66. Recursion Pharmaceuticals has a twelve month low of $4.97 and a twelve month high of $15.74. The stock has a market cap of $1.78 billion, a P/E ratio of -4.00 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $6.82, for a total transaction of $78,068.54. Following the completion of the sale, the director now owns 7,144,216 shares in the company, valued at approximately $48,723,553.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $6.82, for a total value of $78,068.54. Following the completion of the transaction, the director now owns 7,144,216 shares in the company, valued at $48,723,553.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company's stock, valued at approximately $3,939,803.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 201,682 shares of company stock worth $1,322,013. 15.75% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RXRX. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, July 11th. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Finally, Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.